Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Salbutamol + sodium cromoglycate is a fixed-dose combination of two inhaled drugs used primarily for the management of moderate-to-severe asthma, especially in children. Salbutamol (also known as albuterol) is a selective beta-2-adrenoreceptor agonist that acts as a bronchodilator, providing rapid relief from bronchospasm by relaxing airway smooth muscle. Sodium cromoglycate (also known as cromolyn sodium) is a mast cell stabilizer that prevents the release of inflammatory mediators from sensitized mast cells, thereby reducing airway inflammation and hyperresponsiveness. The combination has been shown to provide better control of asthma symptoms than either agent alone and is generally well tolerated with few adverse effects[1][4]. It is typically administered via nebulization.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on salbutamol + sodium cromoglycate.